EarliPoint Health Launches Project ALIGN to Advance Objective Measurement and Outcomes in Autism Care

Learn More →

Articles

Exploring the science, practice, and people shaping the future of early developmental evaluation.

The Right Dose: Treatment Intensity, Evidence, and Earning Payer Trust in ABA

For years, one number has had an outsized influence on conversations about ABA: 40 hours per week. It appears in discussions between […]

…

ADI-R Scoring, Cutoffs, and Interpretation: A Clinician’s Guide

ADI-R scoring follows a defined sequence. A trained interviewer codes a caregiver’s responses to 93 items, a selected subset of those codes […]

…

Autism Assessment Age Ranges: The Complete Reference Chart

Autism assessment tools each publish a specific age range, and the ranges do not line up neatly: the M-CHAT-R/F screens toddlers at […]

…

CARS-2 Scoring Guide: ST vs HF, Cutoff Scores, and Age Ranges

CARS-2 scoring follows a consistent sequence. A trained clinician rates 15 items on a scale of 1 to 4, using half-point midpoints […]

…

Before We Ask Children to Learn Socially, Are the Foundations in Place?

Dr. Cheryl Tierney from EarliPoint Health and Rose Griffin from ABA Speech came together around this topic because we both see value […]

…

Who Can Diagnose Autism? A Scope-of-Practice Reference for Providers

Autism is diagnosed by licensed clinicians whose scope of practice includes diagnosing medical and developmental conditions. In the United States, that means […]

…
Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder